Cost

How to Get GLP-1 Medications Without Insurance

GLP-1 Companion · 9 min read

For uninsured patients, the biggest mistake is asking "where can I get GLP-1 cheapest?" before asking "what exactly am I paying for?" A low advertised monthly number can exclude labs, refills, dose changes, shipping, follow-up visits, or the medication itself.

My position: without insurance, you need a written monthly budget before you buy. That budget should include the medication path, clinical visit fees, lab requirements, refill fees, shipping, dose increases, and what happens if the first medication is not appropriate.

List Prices vs. What You Might Actually Pay

It is important to distinguish between the Wholesale Acquisition Cost (WAC) — the manufacturer's list price — and what uninsured patients actually pay through various programs. List prices serve as a negotiating anchor between manufacturers and pharmacy benefit managers; they rarely reflect real-world costs for individuals who seek assistance.

• Ozempic (semaglutide 0.5–2 mg): list price approximately $935/month; with GoodRx at select pharmacies, $800–$870; with NovoCare PAP, potentially $0 for qualifying patients
• Wegovy (semaglutide 2.4 mg): list price approximately $1,350/month; Novo Nordisk savings card brings it to $0–$99 for commercially insured patients only; PAP for qualifying uninsured patients
• Mounjaro (tirzepatide for T2D): list price approximately $1,060/month; Lilly savings card up to $573 off for commercially insured; Lilly Cares PAP for uninsured
• Zepbound (tirzepatide for obesity): list price approximately $1,060/month; same Lilly savings structure; self-pay vials program through LillyDirect
• Rybelsus (oral semaglutide): list price approximately $935/month; generic versions expected as early as 2026 under patent settlements

Manufacturer Patient Assistance Programs

Both Novo Nordisk and Eli Lilly operate income-based patient assistance programs (PAPs) that can provide GLP-1 medications at no cost or nominal cost to qualifying uninsured patients. These programs are distinct from savings cards, which require commercial insurance.

NovoCare Patient Assistance Program

NovoCare is Novo Nordisk's patient assistance program covering Ozempic, Wegovy, Rybelsus, and other Novo medications. Eligibility is generally limited to U.S. residents who are uninsured or underinsured and whose household income falls at or below 400% of the federal poverty level (approximately $60,000 for a single individual or $124,000 for a family of four in 2026). Applications require a completed form, proof of income, and a prescription signed by your healthcare provider. Processing typically takes two to four weeks.

Lilly Cares Foundation

The Lilly Cares Foundation provides free Mounjaro and Zepbound to eligible uninsured patients. Income limits and application documentation requirements are similar to NovoCare. Lilly also operates LillyDirect, a direct-to-patient pharmacy platform that offers Zepbound single-dose vials at a self-pay price of approximately $399 to $549 per month depending on dose — significantly below the retail pen price — for patients who do not qualify for full assistance.

GoodRx and Discount Pharmacy Platforms

GoodRx, RxSaver, and similar platforms negotiate discounted cash prices with pharmacies. For GLP-1 medications, GoodRx prices tend to be 5 to 15 percent below the retail cash price, which still leaves them expensive for uninsured patients — but the savings are meaningful if you are not eligible for a PAP. GoodRx Gold membership ($9.99/month) occasionally offers additional discounts on specific medications. Always compare GoodRx prices across multiple pharmacies in your area, as prices can vary by $50 to $150 per month for the same drug and dose.

Telehealth Platforms with Self-Pay Pricing

Several telehealth platforms have built self-pay GLP-1 programs that bundle the clinical consultation, prescription, and medication delivery into a single monthly subscription. These platforms often leverage compounding pharmacies (when drugs are on the FDA shortage list) or the LillyDirect vial program to offer lower effective costs.

• Hims & Hers: offered compounded semaglutide during shortage periods; transitioning to brand-name pathway as shortage resolves; subscription pricing varies by program
• Ro Body: self-pay GLP-1 program with bundled clinical care; pricing depends on medication and dose tier
• Found: monthly membership includes clinical visits and prescription management; separate medication cost
• Henry: focuses on affordable access; flat-fee consultation model
• Noom Med: GLP-1 prescribing integrated with behavioral coaching; subscription includes medication management

Pricing on these platforms changes frequently. Always verify current costs on the platform's website and confirm what is included — some bundle medication, while others charge separately for the clinical subscription and the pharmacy fill.

Oral GLP-1 Alternatives

The oral GLP-1 landscape is expanding rapidly, creating more affordable access options for some patients.

• Orforglipron: Eli Lilly's once-daily oral GLP-1 receptor agonist received FDA approval in 2025 for type 2 diabetes and is expected to launch for obesity in 2026. With commercial insurance, the savings card program targets a $25/month copay. For uninsured patients, Lilly Cares assistance is expected to apply. Orforglipron does not require the specialized absorption conditions of Rybelsus, making it simpler to take.
• Rybelsus (oral semaglutide): currently available, though at the same high list price as injectable semaglutide. Generic semaglutide entry under patent settlement agreements could bring prices down significantly by late 2026 or 2027.
• Danuglipron: Pfizer's once-daily oral GLP-1 candidate is in late-stage trials and may offer another oral option in 2027.

State-Specific Assistance Programs

Some states operate pharmaceutical assistance programs for residents who do not qualify for federal assistance. California's CalRx initiative, for example, is designed to negotiate lower drug prices for residents. Several states have 340B programs that allow qualifying health centers to purchase medications at significantly reduced prices and pass those savings to uninsured patients. Community health centers (federally qualified health centers, or FQHCs) are a particularly valuable resource — they serve patients regardless of ability to pay and often have access to 340B drug pricing for GLP-1 medications.

Realistic Cost Scenarios for Uninsured Patients

Here is a realistic breakdown of what an uninsured patient might actually pay per month in 2026, depending on their situation.

• Income below 400% FPL, uninsured: $0/month through NovoCare (Ozempic/Wegovy) or Lilly Cares (Mounjaro/Zepbound) PAP programs — but requires paperwork and 2-4 week processing time
• Income above 400% FPL, uninsured: $399–$549/month for Zepbound vials via LillyDirect self-pay; $800–$870/month for Ozempic via GoodRx
• Orforglipron with commercial insurance savings card (when available): approximately $25–$150/month depending on dose
• Compounded semaglutide from a reputable 503B facility (if available): $150–$400/month; note FDA shortage status has resolved for most doses as of early 2026
• Via FQHC with 340B pricing: potentially $0–$50/month copay depending on the health center's pricing structure

The single most impactful step an uninsured patient can take is to apply for a manufacturer patient assistance program. The application process is straightforward and the potential savings — going from $1,000+ to $0 per month — are enormous. Start there before assuming GLP-1 treatment is out of reach.

A Practical Starting Point

If you are uninsured and need a GLP-1 medication, start by getting a prescription from a licensed provider (telehealth is an option if you do not have a primary care doctor), then immediately apply for the manufacturer PAP for the prescribed medication. While that application is being processed, ask whether a federally qualified health center near you has 340B drug access or whether the prescribing platform offers any bridge pricing. With persistence, many patients can access these medications at a cost far below the headline list price.

The buyer sequence is: check eligibility, compare providers at /partners, ask for the full monthly cost in writing, then decide whether the plan is sustainable for 6-12 months. A cheap first month that you cannot continue is not access; it is a restart waiting to happen.

Sources

• Wilding et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM.
• Jastreboff et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. NEJM.